Drug Database
YE

yellow fever vaccine (Arilvax)

✓ Approved

Novartis AG · Vaccine · Vaccine

What is yellow fever vaccine?

yellow fever vaccine is a vaccine developed by Novartis AG. It is approved for therapeutic indications via injectable (others) or subcutaneous injection.

Drug Profile

Brand NamesArilvax
CompanyNovartis AG
Drug ClassVaccine, Large Molecules
RouteInjectable (Others), Subcutaneous Injection
StatusApproved
Sources: ClinicalTrials.gov, Novartis AG

Therapeutic Indications

yellow fever vaccine is developed for 1 unique indication across 1 therapeutic area.

Therapeutic AreaConditionPhase
Infections and infestationsYellow fever✓ Approved

Related Research Articles

PubMedKidney medicine2026-08-30

COVID-19 Vaccine Knowledge, Practice, and Attitudes Among Hemodialysis Patients in Egypt, Kenya, and Cameroon: A Multicenter Study.

Elsayed Enass E, Kotb Khaled M KM, Heiba Ahmed A, Elhussini Manal Shaker MS et al.

Patients receiving hemodialysis (HD) are at increased risk of severe coronavirus disease 2019 (COVID-19) and were prioritized for vaccination, yet vaccine hesitancy remains common. We assessed COVID-19 vaccine knowledge, acceptance, and attitudes among patients receiving HD in Egypt, Kenya, and Cameroon and identified factors associated with vaccine acceptance, prior infection, willingness to receive future doses, and postvaccination complications. Multicenter cross-sectional survey study. Between March 2021 and April 2022, 765 patients receiving maintenance HD and 196 non-dialysis controls were recruited from dialysis centers in Egypt, Kenya, and Cameroon. Sociodemographic characteristics, clinical comorbidities, prior COVID-19, sources of vaccine information, and exposure to vaccinated or infected relatives. COVID-19 vaccine acceptance, willingness to receive future doses, prior infection, and post-vaccination complications. Structured questionnaires assessed knowledge, practices, and attitudes toward COVID-19 vaccination. Multivariable logistic regression identified factors independently associated with study outcomes. Vaccine acceptance was lower among patients receiving HD than nondialysis controls (58.2% vs 96.2%). Fear of side effects was the most common reason for refusal (39.3%). Postvaccination complications were less frequent among patients receiving HD (22.3% vs 44.3%). Hesitancy was more common among women, younger participants, and those with comorbidities or no prior COVID-19. Having vaccinated or previously infected relatives was associated with a greater willingness to receive future doses. Cross-sectional design limits causal inference. Nonprobability sampling and unmatched controls may limit generalizability. COVID-19 cases may have been underreported because of limited testing. COVID-19 vaccine hesitancy among patients receiving HD is driven by fear, misinformation, and sociodemographic factors. Targeted education and improved access to reliable vaccine information may help increase uptake in this population.

PMID 42668537
Read full article →
PubMedNational science review2026-08-30

Tetraboron MR framework with ortho-B-π-B pattern enables high-efficiency yellow narrowband OLEDs.

Zhang Shuqi S, Yang Yongliu Y, Cheng Zhangli Z, Zhang Tongyuan T et al.

Multiple resonance (MR) frameworks with ortho-boron-π-boron (B-π-B) patterns are promising alternatives to those with para-B-π-B ones for realizing bathochromic narrowband emission, but such cases have been rarely reported, and suffer from significant synthetic challenges. Here, a novel tetraboron MR framework ICZ4B incorporating an ortho-B-π-B pattern was constructed by using indolo[2,3-c]carbazole as the central building block. The well-defined borylation active sites facilitate an efficient one-shot quadruple borylation. ICZ4B not only exhibits bright yellow emission with a small full width at half maximum of 24 nm, but also achieves an improved reverse intersystem crossing rate of 4.7 × 104 s-1. The non-sensitized device realizes an outstanding external quantum efficiency of 36.5%, representing one of the highest results at long wavelengths. This study not only presents a feasible pathway for realizing MR frameworks with ortho-B-π-B patterns via delicate selection of key precursors, but also offers insights for optimizing synthetic strategies for complex MR frameworks.

PMID 42668809
Read full article →
PubMedEMBO molecular medicine2026-08-30

A cavity-reduced prefusion RSV F bivalent vaccine elicits durable and protective immunity.

Liu Lijie L, Yan Mengrong M, Liang Ruoxu R, Wu Qingxin Q et al.

Respiratory syncytial virus (RSV) remains a major cause of severe respiratory disease, and stabilization of the prefusion (preF) conformation of the F glycoprotein is central for vaccine development. Here, we report a structure-guided engineering strategy that enhances preF stability by reducing the hydrophobic cavity within the trimeric F protein. Targeted modifications at metastability-associated sites generated RVF-88, a disulfide-free stabilized preF immunogen that preserves key neutralizing epitopes, including antigenic site Ø, while exhibiting improved structural integrity and long-term storage stability. Formulated as an unadjuvanted bivalent vaccine, RVF-88 elicited potent neutralizing antibody responses and durable immune protection lasting up to 5 months in mice. Vaccination also protected both mice and cotton rats against RSV challenge. Structural analyses confirmed the intended cavity-reduction design, revealing a reduced apical hydrophobic cavity volume and surface area while maintaining the prefusion architecture. Together, these findings establish hydrophobic cavity reduction as a rational strategy for stabilizing prefusion RSV F and provide a promising next-generation vaccine candidate with improved stability and immunogenicity for further clinical development.

PMID 42668284
Read full article →
PubMedJapanese journal of infectious diseases2026-08-30

Immunogenicity and Safety of the 9-valent Human Papillomavirus (HPV) Vaccine Administered as 2-Dose or 3-Dose Regimens in Japanese Boys and Girls Aged 9-15 Years.

Takeuchi Yuzuru Y, Yonekawa Motoharu M, Murata Shinya S, Nakagomi Mariko M et al.

A phase III open-label study evaluated the immunogenicity and safety of the 9-valent human papillomavirus (9vHPV) vaccine in Japanese boys and girls. Japanese boys aged 9-15 years (n = 105) received a 3-dose (Day 1, Month 2, and Month 6) regimen; Japanese boys (n = 104) and girls aged 9-14 years (n = 105) received a 2-dose (Day 1 and Month 6) regimen. Antibody responses to HPV6/11/16/18/31/33/45/52/58 were assessed at Month 7, 18, and 30 using a competitive Luminex immunoassay. Injection-site adverse events (AEs; Days 1 to 5 post-dose), systemic AEs (Days 1 to 15 post-dose), and serious AEs (duration of study) were assessed. At Month 7, for HPV types targeted by the 9vHPV vaccine, seroconversion rates were 100% in all three arms, and in cross-study comparisons with efficacy studies, anti-HPV geometric mean titers in boys were noninferior to those in Japanese men aged 16-26 years, and in girls were noninferior to those in Japanese women aged 16-26 years. Most injection-site AEs were mild to moderate in intensity. No deaths or vaccine-related serious AEs were observed. These results support immunobridging of efficacy findings in Japanese men and women to Japanese boys and girls. The 9vHPV vaccine was generally well tolerated.

PMID 42669546
Read full article →
PubMedVaccine2026-08-30

Ethical considerations of incentive structures in vaccine acceptance research.

Musrati Mohamed Amer MA, Shenaisheh Salem S, Elemraid Mohamed A MA

PMID 42669239
Read full article →
PubMedJournal of clinical and experimental hematopathology : JCEH2026-08-30

Successful treatment of refractory hemophagocytic lymphohistiocytosis complicating Epstein-Barr virus-positive classic Hodgkin lymphoma with rituximab.

Ichikawa Satoshi S, Suzuki Yutaka Y, Tanaka Yuya Y, Kanba Keita K et al.

Hemophagocytic lymphohistiocytosis (HLH) complicating classic Hodgkin lymphoma (HL-HLH) is a rare but frequently life-threatening condition that is strongly associated with Epstein-Barr virus (EBV) infection, particularly in the mixed-cellularity and lymphocyte-depleted subtypes. No consensus has been reached regarding treatment for HL-HLH, and the myelotoxicity induced by etoposide-based HLH-directed therapy precludes its safe addition to intensive lymphoma-directed chemotherapy, particularly in older patients. We here report the case of a male in his early 70s with advanced EBV-positive mixed-cellularity classic Hodgkin lymphoma (CHL) who presented with cervical lymphadenopathy, fever, hepatosplenomegaly, and a markedly elevated soluble interleukin-2 receptor (sIL-2R) level, along with a high peripheral blood EBV DNA load. EBV-encoded small RNA in situ hybridization confirmed EBV positivity in lymphoma cells. His fever was steroid-refractory, and chemotherapy with brentuximab vedotin, doxorubicin, vinblastine, and dacarbazine (BV-AVD) was initiated immediately following the diagnosis was confirmed. However, the persistent high fever did not resolve, and progressive cytopenia, marked hyperferritinemia, and further increase in sIL-2R levels were observed. Repeat bone marrow examinations revealed macrophage activation with hemophagocytosis, confirming HLH as a complication. Rituximab was promptly administered, and the fever resolved within 3 days. Furthermore, ferritin, sIL-2R, and lactate dehydrogenase levels substantially declined within 1 week, with peripheral blood EBV DNA becoming undetectable. BV-AVD was continued without major complications and led to a complete response after six cycles. Rituximab may represent a strategically timed and reasonable adjunctive intervention for EBV-driven HL-HLH that is refractory to, or develops following, chemotherapy for CHL.

PMID 42669549
Read full article →

+9996 more articles available with a free account

Sign up free to view all articles →

Ask about yellow fever vaccine